STATISTICAL CONSIDERATIONS IN THE DESIGN, CONDUCT AND ANALYSES OF ANTIEMETIC CLINICAL-TRIALS - AN EMERGING CONSENSUS

Various aspects of trial design and planning for clinical testing of a ntiemetic therapies administered to cancer patients are considered. It is generally felt that a randomized double-blind parallel-arm design is the best. Ways of achieving adequate power of such studies are disc ussed briefly, as is the need for previous identification of primary a nd secondary end-points. Finally, summary recommendations are given.